Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | OGT | O15294 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11278121 | 0.73 | LMNA (0.43) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL2873513 | 0.66 | — | — | |
| SCHEMBL137702 | 0.64 | LMNA (0.41) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL10507443 | 0.64 | LMNA (0.41) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL472442 | 0.64 | LMNA (0.41) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL10827106 | 0.64 | PYGM (0.34) | — | |
| Water SCHEMBL2773218 | 0.62 | LMNA (0.39) | LMNAKDM4EOGTUSP2MAPT | |
| Dimethylbarbiturate SCHEMBL31271990 | 0.62 | LMNA (0.46) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL8609376 | 0.62 | LMNA (0.39) | LMNAKDM4EOGTUSP2MAPT | |
| SCHEMBL4875346 | 0.62 | LMNA (0.39) | LMNAKDM4EOGTUSP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114430068-A | Lithium ion battery electrolyte | 深圳市研一新材料有限责任公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-2059519-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20110152259-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PALANI ANANDAN | 2011-06-23 | — | — | US | disclosed |
| US-20100227873-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-09-09 | — | — | US | disclosed |
| US-7737155-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-06-15 | — | — | US | disclosed |
| EP-2059519-A2 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008060476-A2 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | LMNA 440/4885KDM4E 2599/4885OGT 942/4885 |
| US-20110152259-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | LMNA 440/4885KDM4E 2599/4885OGT 942/4885 |
| US-20100227873-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | LMNA 440/4885KDM4E 2599/4885OGT 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.